Regeneron Pharmaceuticals Inc.

612.49+5.10+0.84%Vol 780.05K1Y Perf 11.56%
Jun 24th, 2022 16:00 DELAYED
BID612.49 ASK660.00
Open612.06 Previous Close607.39
Pre-Market- After-Market613.03
 - -  0.54 0.09%
Target Price
676.92 
Analyst Rating
Moderate Buy 2.07
Potential %
10.52 
Finscreener Ranking
★★★★     54.56
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★★     63.19
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     69.68
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
39.80 
Earnings Rating
Strong Buy
Market Cap67.28B 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.09
Beta0.24 

Today's Price Range

602.52613.15

52W Range

523.29747.42

5 Year PE Ratio Range

12.7070.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
5.43%
1 Month
-11.35%
3 Months
-9.93%
6 Months
-2.06%
1 Year
11.56%
3 Years
95.75%
5 Years
18.39%
10 Years
437.51%

TickerPriceChg.Chg.%
REGN612.495.10000.84
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
4.00
4.80
0.12
0.14
163.20
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
84.30
55.70
57.40
41.20
48.06
RevenueValueIndustryS&P 500US Markets
16.51B
152.81
29.79
23.16
Earnings HistoryEstimateReportedSurprise %
Q01 20229.3711.4922.63
Q04 202118.4923.7228.29
Q03 20219.8115.3756.68
Q02 20218.8127.97217.48
Q01 20217.7810.0929.69
Q04 20207.118.7222.64
Q03 20209.527.68-19.33
Q02 20205.596.2912.52
Earnings Per EndEstimateRevision %Trend
6/2022 QR9.944.30Positive
9/2022 QR10.53-16.16Negative
12/2022 FY40.63-8.82Negative
12/2023 FY42.90-9.11Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report9.94
Estimates Count8
EPS Growth Next 5 Years %8.00
Volume Overview
Volume780.05K
Shares Outstanding109.85K
Shares Float103.42M
Trades Count23.17K
Dollar Volume475.01M
Avg. Volume801.19K
Avg. Weekly Volume926.62K
Avg. Monthly Volume796.80K
Avg. Quarterly Volume680.15K

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock closed at 612.49 per share at the end of the most recent trading day (a 0.84% change compared to the prior day closing price) with a volume of 780.05K shares and market capitalization of 67.28B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9123 people. Regeneron Pharmaceuticals Inc. CEO is Leonard S. Schleifer.

The one-year performance of Regeneron Pharmaceuticals Inc. stock is 11.56%, while year-to-date (YTD) performance is -3.01%. REGN stock has a five-year performance of 18.39%. Its 52-week range is between 523.2909 and 747.4214, which gives REGN stock a 52-week price range ratio of 39.80%

Regeneron Pharmaceuticals Inc. currently has a PE ratio of 8.20, a price-to-book (PB) ratio of 3.20, a price-to-sale (PS) ratio of 3.80, a price to cashflow ratio of 7.70, a PEG ratio of 2.32, a ROA of 35.96%, a ROC of 43.65% and a ROE of 49.75%. The company’s profit margin is 48.06%, its EBITDA margin is 57.40%, and its revenue ttm is $16.51 Billion , which makes it $152.81 revenue per share.

Of the last four earnings reports from Regeneron Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $9.94 for the next earnings report. Regeneron Pharmaceuticals Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Regeneron Pharmaceuticals Inc. is Moderate Buy (2.07), with a target price of $676.92, which is +10.52% compared to the current price. The earnings rating for Regeneron Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Regeneron Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Regeneron Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.36, ATR14 : 19.78, CCI20 : 3.53, Chaikin Money Flow : -0.07, MACD : -17.00, Money Flow Index : 46.17, ROC : -0.24, RSI : 50.19, STOCH (14,3) : 82.83, STOCH RSI : 1.00, UO : 59.40, Williams %R : -17.17), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Regeneron Pharmaceuticals Inc. in the last 12-months were: Andrew J Murphy (Option Excercise at a value of $4 445 205), Andrew J Murphy (Sold 14 250 shares of value $9 217 524 ), Arthur Frederick Ryan (Sold 914 shares of value $570 288 ), Bonnie L. Bassler (Option Excercise at a value of $3 409 395), Bonnie L. Bassler (Sold 8 816 shares of value $5 541 220 ), Christine A. Poon (Option Excercise at a value of $856 650), Christine A. Poon (Sold 15 000 shares of value $10 021 403 ), Christopher R. Fenimore (Option Excercise at a value of $8 947 436), Christopher R. Fenimore (Sold 4 781 shares of value $3 133 037 ), Daniel P. Van Plew (Option Excercise at a value of $29 507 900), Daniel P. Van Plew (Sold 18 762 shares of value $11 797 750 ), George D. Yancopoulos (Option Excercise at a value of $97 775 812), George D. Yancopoulos (Sold 100 000 shares of value $61 267 263 ), George L. Sing (Sold 23 405 shares of value $14 826 927 ), Huda Y. Zoghbi (Option Excercise at a value of $1 175 760), Huda Y. Zoghbi (Sold 3 000 shares of value $2 000 002 ), Joseph J. Larosa (Option Excercise at a value of $8 956 500), Joseph J. Larosa (Sold 17 051 shares of value $11 457 735 ), Joseph L. Goldstein (Option Excercise at a value of $1 853 861), Joseph L. Goldstein (Sold 4 910 shares of value $3 313 050 ), Leonard S. Schleifer (Option Excercise at a value of $135 842 120), Leonard S. Schleifer (Sold 230 000 shares of value $149 950 270 ), Marc Tessier-Lavigne (Option Excercise at a value of $9 983 380), Marc Tessier-Lavigne (Sold 35 348 shares of value $23 578 800 ), Marion McCourt (Option Excercise at a value of $3 806 523), Marion McCourt (Sold 11 444 shares of value $7 161 330 ), Michael S. Brown (Option Excercise at a value of $5 426 733), Michael S. Brown (Sold 15 305 shares of value $9 734 857 ), N. Anthony Coles (Option Excercise at a value of $7 136 566), N. Anthony Coles (Sold 19 648 shares of value $12 825 783 ), Neil Stahl (Option Excercise at a value of $12 986 925), P. Roy Vagelos (Option Excercise at a value of $26 869 500), P. Roy Vagelos (Sold 24 325 shares of value $16 526 237 ), Robert E. Landry (Option Excercise at a value of $16 568 551), Robert E. Landry (Sold 7 950 shares of value $5 462 158 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (53.33 %)
6 (50.00 %)
8 (57.14 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (33.33 %)
5 (41.67 %)
5 (35.71 %)
Moderate Sell
2 (13.33 %)
1 (8.33 %)
1 (7.14 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.07
Moderate Buy
2.08
Moderate Buy
1.93

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

CEO: Leonard S. Schleifer

Telephone: +1 914 847-7000

Address: 777 Old Saw Mill River Road, Tarrytown 10591-6707, NY, US

Number of employees: 9 123

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

55%45%

Bearish Bullish

55%45%

Bearish Bullish

55%45%

TipRanks News for REGN

Thu, 16 Jun 2022 01:46 GMT Regeneron (REGN) Receives a Hold from RBC Capital

- TipRanks. All rights reserved.

Sat, 11 Jun 2022 09:02 GMT Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Cooper Co (COO)

- TipRanks. All rights reserved.

Fri, 06 May 2022 03:48 GMT Regeneron (REGN) Receives a Hold from Robert W. Baird

- TipRanks. All rights reserved.

Thu, 05 May 2022 16:39 GMT Regeneron (REGN) Gets a Hold Rating from Morgan Stanley

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 10:20 GMT H.C. Wainwright Believes Regeneron (REGN) Wont Stop Here

- TipRanks. All rights reserved.

Thu, 10 Feb 2022 12:35 GMT Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Regeneron (REGN) and Seagen (SGEN)

- TipRanks. All rights reserved.

Mon, 07 Feb 2022 13:35 GMT Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), BellRing Brands (BRBR) and Optinose (OPTN)

- TipRanks. All rights reserved.

Wed, 19 Jan 2022 17:25 GMT Regeneron (REGN) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Tue, 18 Jan 2022 16:30 GMT Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), AlloVir (ALVR) and SI-Bone (SIBN)

- TipRanks. All rights reserved.

News

Stocktwits